Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. The company is headquartered in Malvern, Pennsylvania and currently employs 716 full-time employees. The company went IPO on 2018-06-28. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The firm provides more than 7.1 million treatments to over 1,95,000 patients.
Follow-Up Questions
Neuronetics Inc의 CEO는 누구입니까?
Mr. Keith Sullivan은 2020부터 회사에 합류한 Neuronetics Inc의 President입니다.
STIM 주식의 가격 성능은 어떻습니까?
STIM의 현재 가격은 $2.91이며, 전 거래일에 decreased 0% 하였습니다.
Neuronetics Inc의 주요 사업 주제나 업종은 무엇입니까?
Neuronetics Inc은 Health Care 업종에 속하며, 해당 부문은 Health Care입니다
Neuronetics Inc의 시가총액은 얼마입니까?
Neuronetics Inc의 현재 시가총액은 $192.4M입니다
Neuronetics Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 5명의 분석가가 Neuronetics Inc에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 6명의 매수, 1명의 보유, 0명의 매도, 그리고 2명의 강력한 매도를 포함합니다